Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
出版年份 2022 全文链接
标题
Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
作者
关键词
-
出版物
Nature Communications
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-07-26
DOI
10.1038/s41467-022-31941-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs
- (2022) Mara Gilardi et al. MOLECULAR CANCER THERAPEUTICS
- Interleukin-1 as Innate Mediator of T Cell Immunity
- (2021) Bram Van Den Eeckhout et al. Frontiers in Immunology
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
- (2021) Benjamin Lacas et al. RADIOTHERAPY AND ONCOLOGY
- Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
- (2021) Zhiyong Wang et al. Nature Communications
- Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
- (2021) Rom Leidner et al. Journal for ImmunoTherapy of Cancer
- Head and neck cancer
- (2021) Mayur D Mody et al. LANCET
- Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
- (2021) Hirofumi Shibata et al. Frontiers in Oncology
- Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities
- (2021) Robert Saddawi-Konefka et al. Frontiers in Oncology
- NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity
- (2021) Ghita Ghislat et al. Science Immunology
- Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling
- (2020) Sampath K. Loganathan et al. SCIENCE
- Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
- (2020) Hiroshi Matsuoka et al. BMC CANCER
- The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
- (2020) Nathalie Percie du Sert et al. PLOS BIOLOGY
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
- (2020) David M. Francis et al. Science Translational Medicine
- Head and neck squamous cell carcinoma
- (2020) Daniel E. Johnson et al. Nature Reviews Disease Primers
- Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
- (2019) J. Rogado et al. EUROPEAN JOURNAL OF CANCER
- EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Lisa F. Licitra et al. JOURNAL OF CLINICAL ONCOLOGY
- High-dimensional cell-level analysis of tissues with Ce3D multiplex volume imaging
- (2019) Weizhe Li et al. Nature Protocols
- Functional Organ Preservation Surgery in Head and Neck Cancer: Transoral Robotic Surgery and Beyond
- (2019) Wojciech Golusiński Frontiers in Oncology
- CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention
- (2019) Yan Yan et al. Frontiers in Cell and Developmental Biology
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Chemokine and chemotactic signals in dendritic cell migration
- (2018) Laura Tiberio et al. Cellular & Molecular Immunology
- Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
- (2018) Ariel E. Marciscano et al. CLINICAL CANCER RESEARCH
- A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR
- (2018) L. Siu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
- (2018) Hisham Mehanna et al. LANCET
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Double-slit photoelectron interference in strong-field ionization of the neon dimer
- (2018) Maksim Kunitski et al. Nature Communications
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues
- (2017) D Sichien et al. Mucosal Immunology
- Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
- (2017) Kenji Chamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
- (2017) Adam Diehl et al. Oncotarget
- Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma
- (2017) Paul Zolkind et al. Oncotarget
- Genomic predictive model for recurrence and metastasis development in head and neck squamous cell carcinoma patients
- (2017) Ilda Patrícia Ribeiro et al. Scientific Reports
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation
- (2016) Jernej Godec et al. IMMUNITY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer
- (2015) Anil K. D’Cruz et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
- (2015) Harrison Cash et al. Oncotarget
- Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow
- (2014) C. T. Mayer et al. BLOOD
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Critical Roles of a Dendritic Cell Subset Expressing a Chemokine Receptor, XCR1
- (2013) C. Yamazaki et al. JOURNAL OF IMMUNOLOGY
- Development and validation of a treatment planning system for small animal radiotherapy: SmART-Plan
- (2013) Stefan J. van Hoof et al. RADIOTHERAPY AND ONCOLOGY
- Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer
- (2012) Nancy P. Judd et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Type I interferon response and innate immune sensing of cancer
- (2012) Mercedes B. Fuertes et al. TRENDS IN IMMUNOLOGY
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model
- (2009) R. Czerninski et al. Cancer Prevention Research
- Chemical Carcinogenesis Models for Evaluating Molecular-Targeted Prevention and Treatment of Oral Cancer
- (2009) L. Vitale-Cross et al. Cancer Prevention Research
- Decision analysis and treatment threshold in a management for the N0 neck of the oral cavity carcinoma
- (2009) Masaya Okura et al. ORAL ONCOLOGY
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
- (2009) Jean-Pierre Pignon et al. RADIOTHERAPY AND ONCOLOGY
- Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity
- (2008) K. Hildner et al. SCIENCE
- Lymph node mapping in the mouse
- (2007) Maria I. Harrell et al. JOURNAL OF IMMUNOLOGICAL METHODS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started